127 related articles for article (PubMed ID: 7571965)
1. Pituitary adenomas. Correlation of the cytologic appearance with biologic behavior.
Pegolo G; Buckwalter JG; Weiss MH; Hinton DR
Acta Cytol; 1995; 39(5):887-92. PubMed ID: 7571965
[TBL] [Abstract][Full Text] [Related]
2. p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions.
Thapar K; Scheithauer BW; Kovacs K; Pernicone PJ; Laws ER
Neurosurgery; 1996 Apr; 38(4):765-70; discussion 770-1. PubMed ID: 8692397
[TBL] [Abstract][Full Text] [Related]
3. Clinical tumor growth and comparison with proliferation markers in non-functioning (inactive) pituitary adenomas.
Saeger W; Lüdecke B; Lüdecke DK
Exp Clin Endocrinol Diabetes; 2008 Feb; 116(2):80-5. PubMed ID: 18072009
[TBL] [Abstract][Full Text] [Related]
4. Pathobiology of pituitary adenomas and carcinomas.
Scheithauer BW; Gaffey TA; Lloyd RV; Sebo TJ; Kovacs KT; Horvath E; Yapicier O; Young WF; Meyer FB; Kuroki T; Riehle DL; Laws ER
Neurosurgery; 2006 Aug; 59(2):341-53; discussion 341-53. PubMed ID: 16883174
[TBL] [Abstract][Full Text] [Related]
5. Topoisomerase IIalpha expression in pituitary adenomas and carcinomas: relationship to tumor behavior.
Vidal S; Kovacs K; Horvath E; Rotondo F; Kuroki T; Lloyd RV; Scheithauer BW
Mod Pathol; 2002 Nov; 15(11):1205-12. PubMed ID: 12429800
[TBL] [Abstract][Full Text] [Related]
6. [Immunohistochemistry for pituitary hormones and Ki-67 in growth hormone producing pituitary adenomas].
Brito J; Sáez L; Lemp M; Liberman C; Michelsen H; Araya AV
Rev Med Chil; 2008 Jul; 136(7):831-6. PubMed ID: 18949157
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical analysis of tumor angiogenic factors in human pituitary adenomas.
Niveiro M; Aranda FI; Peiró G; Alenda C; Picó A
Hum Pathol; 2005 Oct; 36(10):1090-5. PubMed ID: 16226108
[TBL] [Abstract][Full Text] [Related]
8. Flow cytometric DNA ploidy and cells phase fractions in recurrent human pituitary adenomas. A correlative study of flow cytometric analysis and the expression of proliferating cell nuclear antigen.
Chae YS; Flotte T; Hsu DW; Preffer F; Hedley-Whyte ET
Gen Diagn Pathol; 1996 Oct; 142(2):89-95. PubMed ID: 8950573
[TBL] [Abstract][Full Text] [Related]
9. Expression of cell proliferation markers in pituitary adenomas--correlation and clinical relevance of MIB-1 and anti-topoisomerase-IIalpha.
Wolfsberger S; Wunderer J; Zachenhofer I; Czech T; Böcher-Schwarz HG; Hainfellner J; Knosp E
Acta Neurochir (Wien); 2004 Aug; 146(8):831-9. PubMed ID: 15254805
[TBL] [Abstract][Full Text] [Related]
10. Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients.
Trouillas J; Labat-Moleur F; Sturm N; Kujas M; Heymann MF; Figarella-Branger D; Patey M; Mazucca M; Decullier E; Vergès B; Chabre O; Calender A;
Am J Surg Pathol; 2008 Apr; 32(4):534-43. PubMed ID: 18300794
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis of pituitary adenomas on touch preparations assisted by immunocytochemistry.
Kontogeorgos G; Bassiouka I; Giannou P; Vamvassakis E; Rologis D; Orphanidis G
Acta Cytol; 1995; 39(2):141-52. PubMed ID: 7887060
[TBL] [Abstract][Full Text] [Related]
12. [Pituitary adenomas: relationship between invasiveness and proliferative cell nuclear index].
Tella Junior OI; Herculano MA; Delcelo R
Arq Neuropsiquiatr; 2000 Dec; 58(4):1055-63. PubMed ID: 11105073
[TBL] [Abstract][Full Text] [Related]
13. Proliferation activity in pituitary adenomas: measurement by monoclonal antibody Ki-67.
Knosp E; Kitz K; Perneczky A
Neurosurgery; 1989 Dec; 25(6):927-30. PubMed ID: 2601824
[TBL] [Abstract][Full Text] [Related]
14. Multiregional sampling reveals a homogenous distribution of Ki-67 proliferation rate in pituitary adenomas.
Wolfsberger S; Kitz K; Wunderer J; Czech T; Boecher-Schwarz HG; Hainfellner JA; Knosp E
Acta Neurochir (Wien); 2004 Dec; 146(12):1323-7; discussion 1327-8. PubMed ID: 15480830
[TBL] [Abstract][Full Text] [Related]
15. Determination of Ki-67 labeling index in pituitary adenomas using MIB-1 monoclonal antibody.
Lath R; Chacko G; Chandy MJ
Neurol India; 2001 Jun; 49(2):144-7. PubMed ID: 11447433
[TBL] [Abstract][Full Text] [Related]
16. Indices of apoptosis and proliferation as potential prognostic markers in non-functioning pituitary adenomas.
Ibrahim AE; Pickering RM; Gawne-Cain ML; King S; Lees PD; Ellison DW
Clin Neuropathol; 2004; 23(1):8-15. PubMed ID: 14986928
[TBL] [Abstract][Full Text] [Related]
17. A clinicopathological and immunohistochemical study of clinically non-functioning pituitary adenomas: a single institutional experience.
Rishi A; Sharma MC; Sarkar C; Jain D; Singh M; Mahapatra AK; Mehta VS; Das TK
Neurol India; 2010; 58(3):418-23. PubMed ID: 20644271
[TBL] [Abstract][Full Text] [Related]
18. Biologic markers of invasive pituitary adenomas involving the sphenoid sinus.
Gandour-Edwards R; Kapadia SB; Janecka IP; Martinez AJ; Barnes L
Mod Pathol; 1995 Feb; 8(2):160-4. PubMed ID: 7777477
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic correlates of giant pituitary adenomas.
Chacko G; Chacko AG; Lombardero M; Mani S; Seshadri MS; Kovacs K; Scheithauer BW
J Clin Neurosci; 2009 May; 16(5):660-5. PubMed ID: 19285407
[TBL] [Abstract][Full Text] [Related]
20. [Significance of p53 protein expression and proliferative potential with MIB-1 on tumor recurrence of pituitary adenomas].
Miyagami M; Nakamura S
No To Shinkei; 1998 Jan; 50(1):27-32. PubMed ID: 9493195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
